國立科技(300716.SZ):控股股東擬協議轉讓5.06%的股份予楊國芬
格隆匯3月7日丨國立科技(300716.SZ)公佈,公司控股股東東莞市永綠實業投資有限公司與楊國芬於2022年3月7日簽署了《股份轉讓協議》,東莞市永綠實業投資有限公司(“永綠投資”、“轉讓方”)擬將其持有的國立科技810萬股無限售流通股份(佔目前公司總股本5.06%),通過協議轉讓的方式轉讓給楊國芬。
此次權益變動前,控股股東永綠投資持有公司股份數量為6364.9895萬股,佔公司總股本的39.78%;此次權益變動後,永綠投資持有公司股份5554.9895萬股,佔公司總股本的34.71%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.